InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Enliven Therapeutics, Inc.

ELVN Clue Score23
United States Fiscal year ends December CIK 0001672619
$40.98 +0.86% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $40.98 +953.47% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Mar 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2019Operating income−24.1Net income−23.5Fiscal year 2020Operating income−41.7Net income−41.4Fiscal year 2021Operating income−51.4Net income−51.4EPS, diluted−2.37Fiscal year 2022Operating income−38.8Net income−37.7EPS, diluted−12.05Fiscal year 2023Operating income−83.5Net income−71.6EPS, diluted−2.01Fiscal year 2024Operating income−104.6Net income−89.0EPS, diluted−1.89Fiscal year 2025Operating income−119.7Net income−103.7EPS, diluted−1.83
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −24.1 −41.7 −51.4 −38.8 −83.5 −104.6 −119.7
Net income −23.5 −41.4 −51.4 −37.7 −71.6 −89.0 −103.7
Growth
EPS, diluted n/a n/a −2.37 −12.05 −2.01 −1.89 −1.83

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−21.9Capital expenditure−0.1Free cash flow−22.0Fiscal year 2020Operating cash flow−37.4Capital expenditure−0.0Free cash flow−37.4Fiscal year 2021Operating cash flow−46.8Capital expenditure−0.0Free cash flow−46.8Fiscal year 2022Operating cash flow−32.1Capital expenditure−0.6Free cash flow−32.7Fiscal year 2023Operating cash flow−61.3Capital expenditure−0.1Free cash flow−61.4Fiscal year 2024Operating cash flow−73.2Capital expenditure−0.0Free cash flow−73.2Fiscal year 2025Operating cash flow−70.3Capital expenditure−0.2Free cash flow−70.5
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −21.9 −37.4 −46.8 −32.1 −61.3 −73.2 −70.3
Capital expenditure −0.1 −0.0 −0.0 −0.6 −0.1 −0.0 −0.2
Free cash flow −22.0 −37.4 −46.8 −32.7 −61.4 −73.2 −70.5
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2019Cash4.9Shareholders’ equity−48.8Fiscal year 2020Cash47.7Shareholders’ equity84.4Fiscal year 2021Cash48.3Shareholders’ equity−42.9Fiscal year 2022Cash75.5Shareholders’ equity−76.8Fiscal year 2023Cash100.1Shareholders’ equity245.9Fiscal year 2024Cash124.1Shareholders’ equity309.8Fiscal year 2025Cash98.9Shareholders’ equity459.6
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 4.9 47.7 48.3 75.5 100.1 124.1 98.9
Shareholders’ equity −48.8 84.4 −42.9 −76.8 245.9 309.8 459.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023† 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
19.0 32.2 38.4 31.0 64.6 80.8 85.9
5.1 9.5 13.0 7.8 19.0 23.8 33.8
−24.1 −41.7 −51.4 −38.8 −83.5 −104.6 −119.7
Growth
n/a n/a −51.4 1.6 n/a n/a n/a
n/a n/a n/a 0.0 0.0 0.2 0.0
−23.5 −41.4 −51.4 −37.7 −71.6 −89.0 −103.7
Growth
Per share
n/a n/a −2.37 −12.05 −2.01 −1.89 −1.83
n/a n/a −2.37 −12.05 −2.01 −1.89 −1.83
Growth
n/a n/a 21.7 3.1 35.5 47.1 56.7
n/a n/a 21.7 3.1 35.5 47.1 56.7
Growth −85.6% +1,037.7% +32.4% +20.4%

† The diluted share count jumps at 2022 and 2023, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 7 of 7 years on file.